Literature DB >> 1444881

Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications.

G S Smith1, M J de Leon, A E George, A Kluger, N D Volkow, T McRae, J Golomb, S H Ferris, B Reisberg, J Ciaravino.   

Abstract

Positron emission tomographic studies of cerebral glucose metabolism have shown high diagnostic specificity in distinguishing among the degenerative dementias and differentiating between Alzheimer's disease (AD) and normal aging. The current investigation was undertaken to characterize the regional glucose metabolic deficits in AD, using cross-sectional and longitudinal study designs. All subjects met the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for AD (n = 45) or were normal (n = 20), and the AD subjects were subdivided into incipient and mild AD and moderate plus moderately severe subgroups based on the Global Deterioration Scale. The subjects underwent a non-contrast computed tomographic scan and a positron emission tomographic (PETT VI) scan. The AD subjects (n = 14) and normal control subjects (n = 15) received evaluations 2 to 3 years after baseline study. The brain regions that show glucose metabolic deficits cross-sectionally (temporal and parietal association areas, with lesser degrees of deficit in subcortical gray matter structures), over the stages of AD, also show further deficits longitudinally within the same AD subjects. The reduction in glucose metabolism is greater than would be expected from the degree of brain atrophy. The glucose metabolic deficits are discussed in the context of neuropathologic findings and neurotransmitter deficits in AD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444881     DOI: 10.1001/archneur.1992.00530350056020

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  43 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

2.  Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4.

Authors:  Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  FASEB J       Date:  2010-05-25       Impact factor: 5.191

Review 3.  The rationale for deep brain stimulation in Alzheimer's disease.

Authors:  Zaman Mirzadeh; Ausaf Bari; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2015-10-06       Impact factor: 3.575

4.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

5.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.

Authors:  Winnie S Liang; Eric M Reiman; Jon Valla; Travis Dunckley; Thomas G Beach; Andrew Grover; Tracey L Niedzielko; Lonnie E Schneider; Diego Mastroeni; Richard Caselli; Walter Kukull; John C Morris; Christine M Hulette; Donald Schmechel; Joseph Rogers; Dietrich A Stephan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

6.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

7.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 8.  Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology.

Authors:  Krithika Vaidyanathan; Sean Durning; Lance Wells
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-14       Impact factor: 8.250

9.  Novel functions of the alpha-ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease.

Authors:  Qingli Shi; Hui Xu; Wayne A Kleinman; Gary E Gibson
Journal:  Biochim Biophys Acta       Date:  2007-12-31

10.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.

Authors:  Nikolaos Scarmeas; Christian G Habeck; Eric Zarahn; Karen E Anderson; Aileen Park; John Hilton; Gregory H Pelton; Matthias H Tabert; Lawrence S Honig; James R Moeller; Davangere P Devanand; Yaakov Stern
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.